‘Prolor’: Positive Results In Human Growth Hormone Trial

Prolor Biotech reported positive results from a Phase II four-month treatment extension study of hGH-CTP, its long-acting version of human growth hormone, in growth hormone deficient adults. The findings show that a single weekly injection of hGH-CTP has the potential to replace seven consecutive daily injections of currently marketed human growth hormone (hGH), and further validates the dosing regimen for the company’s planned Phase III trial. In the Phase II clinical trial, hGH-CTP was administered to growth hormone deficient adults for a period of four weeks.